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Abstract
PLEC, the gene encoding the cytolinker protein plectin, has eight tissue-speciﬁc isoforms in humans, arising by alternate
splicing of the ﬁrst exon. To date, all PLEC mutations that cause epidermolysis bullosa simplex (EBS) were found in exons
common to all isoforms. Due to the ubiquitous presence of plectin in mammalian tissues, EBS from recessive plectin
mutations is always associated with extracutaneous involvement including muscular dystrophy, pyloric atresia and
cardiomyopathy. We studied a consanguineous family with sisters having isolated blistering suggesting EBS. Skin disease
started with foot blisters at walking age and became generalized at puberty while sparing mucous membranes. DNA
sequencing revealed a homozygous nonsense mutation (c.46C>T; p.Arg16X) in the ﬁrst exon of the plectin variant encoding
plectin isoform 1a (P1a). Immunoﬂuorescence antigen mapping, transmission electron microscopy, western blot analysis
and qRT-PCR were performed on patient skin and cultured keratinocytes, control myocardium and striated muscle
samples. We found hypoplastic hemidesmosomes and intra-epidermal ‘pseudo-junctional’ cleavage ﬁtting EBS. Screening
for cardiomyopathy and muscle dystrophy showed no abnormalities. We report the ﬁrst cases of autosomal-recessive EBS
from P1a deﬁciency affecting skin, while mucous membranes, heart and muscle are spared. The dominant expression of
the P1a isoform in epidermal basal cell layer and cultured keratinocytes suggests that mutations in the ﬁrst exon of isoform
1a cause skin-only EBS without extracutaneous involvement. Our study characterizes yet another of the eight isoforms of
plectin and adds a tissue-speciﬁc phenotype to the spectrum of ‘plectinopathies’ produced by mutations of unique ﬁrst
exons of this gene.
Introduction
Epidermolysis bullosa (EB [MIM131900]) is a heterogeneous group
of genodermatoses characterized by lifelong skin fragility and
extracutaneous complications present from birth (1). Affected
individuals suffer from trauma-induced blistering of skin and
mucous membranes with severity ranging from mild to lethal.
For EB, up until now there have been mutations identiﬁed in
18 different genes affecting different proteins in the epidermis
and basement membrane zone (BMZ) (1). Depending on the af-
fected protein, the epidermis is rendered fragile by cleavage of
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the skin at its biological location. The most commonly occurring
subtype is epidermolysis bullosa simplex (EBS) where skin cleav-
age occurs in the epidermis (2). In basal EBS the split occurs in
the basal cell layer as witnessed by immunoﬂuorescence anti-
gen mapping or electron microscopy. Basal EBS is commonly as-
sociated with four different genes: KRT5, KRT14, BPAG1 and
PLEC. In 8% of EBS cases, PLEC is the mutated gene (3). PLEC en-
codes the cytolinker protein plectin, which is ubiquitously pre-
sent in skin, mucous membranes, gut, muscle and heart tissue.
The phenotypes associated with PLEC mutations are mucocuta-
neous blistering, pyloric atresia, muscular dystrophy and cardio-
myopathy (4,5). Here, we identify a novel mutation causing
cutaneous EBS without extracutaneous involvement. This non-
sense mutation found in the distinct ﬁrst exon 1a encoding
the N terminus of plectin isoform 1a (P1a) only disrupts this
one isoformwhose tissue dominant distribution in the epidermis
results in skin-only EBS.
Results
Our index female patient (V:1, EB 315-01) was 27-years old when
referred to our clinic for consultation of her unclassiﬁed EB sub-
type. Shewas one of two affected daughters born to consanguin-
eous Turkish parents (Fig. 1A). Mild blistering began afterwalking
age at 1.5 years and slightly restricted her physical education
activities at school. Both hand and toenails were dystrophic
from the age of 3 years. Blistering became generalized with prur-
itus when in puberty at 14 years and lesions healed with scarring
and hyperpigmentation. Mucous membranes were not affected
and enamel was normal. She displayed excoriated and verrucous
papules and intact blisters (Fig. 1B) most pronounced on the acra
with residual post-inﬂammatory hyperpigmentation (Fig. 1C–E).
Focal plantar hyperkeratosis and severe nail dystrophy on both
hand and toenails was seen (Fig. 1E). Scalp, axillary and pubic
hair was normal. Her one-year younger sister (V:2, EB 315-02)
Figure 1. Clinical picture. (A) Pedigree of family 1 with EBS-plectin 1a. DNAwas obtained from individuals V-1 and V-2. The rest of the family members was unavailable
for consultation. (B–E) Clinical presentation of patient V:1. Generalized verrucous papules, excoriations and post-inﬂammatory hyperpigmentation of abdomen, thighs,
shins and dorsal surface of arms.
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had a similar history and distribution of progressive skin lesions,
however displayed less pronounced hyperkeratotic papules and
plantar hyperkeratosis possibly due to minor pruritus as com-
pared to her sister (Supplementary Material, Fig. S1). Routine
histopathology of a papule revealed dyskeratosis with papillar
inﬂammation of the dermis (Supplementary Material, Fig. S2).
Immunoﬂuorescence antigen mapping of lesional skin showed
a thin granular lining of keratin staining on the blister ﬂoor
revealing a very low intra-epidermal cleavage in basal cells that
led us to the diagnosis of EBS. Double immunoﬂuorescence stain-
ing of intact patient’s skin with afﬁnity-puriﬁed isoform-speciﬁc
rabbit antibodies to P1a and pan-plectinmousemonoclonal anti-
body (mAb) 10F6 recognizing all isoforms of plectin was negative
for P1a (Fig. 2A), but positive for pan-plectin, producing a linear
pattern along the epidermal BMZ, albeit of markedly reduced
intensity compared to control skin (Fig. 2B). In the latter, staining
for P1a revealed the same pattern and intensity of linear ﬂuores-
cence along the BMZ as that for pan-plectin (Fig. 2D–F). The
expression of integrin α6β4 was normal (data not shown). A 1.5-
mm punch biopsy, obtained for ﬁxation and transmission elec-
tron microscopy, revealed hypoplastic hemidesmosomes and
intra-epidermal pseudo-junctional cleavage with the plasma
membrane of basal cells visible on the blister ﬂoor (Fig. 2M and
N). Together, these ﬁndings indicated PLEC as a candidate gene.
DNA was isolated from peripheral blood and mutation analysis
of the coding region of the PLEC gene including exon-intron
boundaries of all 8 isoforms revealed a homozygous nonsense
mutation present in P1a, c.46C>T leading to a premature termin-
ation codon p.Arg16X (Fig. 3A and B). The affected sister of the
index patient was a carrier of the same homozygous mutation.
Further PLEC sequence analysis also revealed a nucleotide transi-
tion in the promoter sequence of isoform 1, c.-27C>T. Following
mutation analysis, immunoﬂuorescence mapping was extended
with isoform-speciﬁc antibodies to P1a and anti-pan-plectin
mAb 10F6 on control striated muscle andmyocardium from nor-
mal cadavers. P1a was not expressed by myocytes in striated
muscle and myocardium, whereas the shared plectin epitope
(10F6) was prominently stained at Z-disks of striated muscle
(Fig. 2H) and intercalated discs of myocardium (Fig. 2K). We also
examined stratiﬁed epithelia other than skin of human controls,
and found expression of P1a along the basement membrane of
the oral cavity mucosa and to a limited extent in the conjunctiva
(Supplementary Material, Fig. S3).
When cell lysates of cultured skin keratinocytes from both of
the affected sisters were subjected to immunoblotting using
mAb 10F6 and antibodies to P1a, reduced 10F6 signals (V:1
16.5% and V:2 15.4%) compared to control cells were observed
in both cases (Fig. 3C, ﬁrst panel), whereas in neither case were
P1a-positive bands detectable (Fig. 3C, second panel). Blot stain-
ing done with antibodies to desmoplakin as a control, for both
patients revealed unchanged signals compared to control cells
(Fig. 3C, third panel).
We performed quantitative RT-PCR (qRT-PCR) on cultured
cells and found dominance of P1a transcription compared to
plectin isoform 1c (P1c) in normal human keratinocytes and
ﬁbroblasts (Fig. 3D). The transcription level of P1a, but not of
P1c, was reduced in patient keratinocytes andﬁbroblasts (Fig. 3D).
We also checked the transcription level of plectin isoforms in
mouse epidermis and keratinocytes to compare with our human
data and to line upwith literature (6). Absolute quantiﬁcation un-
veiled two important differences in isoform expression between
epidermis and primarymouse keratinocytes. While P1c accounts
for a substantial fraction (∼80%) of the plectin transcript in epi-
dermis, this is no longer the case in primary keratinocytes
(∼20%), conversely, P1a transcript levels are higher (more than
50% of total) in primary keratinocytes than in epidermis (∼20%
of total) (Supplementary Material, Fig. S4).
Considering that plectin mutations leading to EBS can mani-
fest with extracutaneous complications of muscle dystrophy
and/or cardiomyopathy (3,4), the index patient was screened by
a neurologist and cardiologist respectively. Upon physical exam-
ination no symptoms of muscular dystrophy were found and a
muscle biopsy was deemed unnecessary. Cardiologic consult-
ation including physical examination, electrocardiogram and
an echocardiogram was carried out with no associated ﬁndings
of cardiomyopathy. Moreover, her affected younger sister had
no symptoms of muscular or cardiologic pathology. Currently
both sisters, nowaged 29 and 30 years, exhibit no signs ofmuscu-
lar dystrophy or cardiomyopathy.
Discussion
The spectrum of diseases in humans caused by PLECmutations,
‘the plectinopathies’, continues to expand and be classiﬁed. The
cytolinker scaffold protein plectin is present in essentially all
mammalian tissue. This cardinal supporting structure is ex-
pressed in tissues such as heart, muscle, striated epithelia as
well as the blood–brain barrier. At the cellular level, plectin
strengthens tissues in regions of mechanical stress, such as link-
ing desmin and the dystrophin glycoprotein complex in myo-
cytes of the heart. In skin, plectin is a fundamental building
block of the hemidesmosome, anchoring basal keratinocytes of
the epidermis to the underlying dermis (7). PLEC is a large gene
consisting of 32 exons with 8 tissue-speciﬁc isoforms which
arise by alternative 5′splicing of transcripts (8–10). Molecularly,
the plectin protein is built of a central α-helical coiled-coil rod do-
main ﬂanked by N- and C-terminal globular domains (11). All 8
isoforms share exons 2-32 and differ only by distinct ﬁrst exons
(4) (Supplementary Material, Table S1). The various isoforms of
plectin continue to be classiﬁed according to occurrence and
tissue speciﬁcity arising from the alternate promoter regions
and cis splicing from several different ﬁrst coding exons (4,7).
The most prominently expressed isoform of plectin in mouse
and human cultured keratinocytes is P1a, followed by P1c and
other isoforms among them P1, plectin isoform 1f (P1f ) and P1b
(Supplementary Material, Fig. S4) (see also Ref. 12).
That P1a is also dominantlyexpressed at the dermal–epidermal
junction of human epidermis is suggested by (i) the identical
pattern and intensity of P1a and pan-plectin staining using
double immunoﬂuorescence labeling of normal human skin
(Fig. 2F), (ii) the severe reduction of the pan-plectin signal in pa-
tient skin (Fig. 2B), (iii) the ∼84% reduction of pan-plectin in pa-
tient keratinocyte extracts (Fig. 3C, ﬁrst panel) and (iv) qRT-PCR
showing a higher level of P1a than P1c transcripts in cultured
human keratinocytes in normal control cell populations
(Fig. 3D). The dominance of P1c transcripts in mouse epidermis
(Supplementary Material, Fig. S4A) is simply explained by the
fact that primary keratinocytes lack the suprabasal layers
where P1c is predominantly expressed while they are rich in
hemidesmosome-like structures where P1a is found.
P1awas expressed also in oralmucosa, and to a limited extent
in conjunctiva (Supplementary Material, Fig. S3). Since P1a is ex-
pressed in these epithelia in normal human controls one may
have expected mucosal lesions in the patients. The fact that
they were absent suggests that in these tissues P1a’s loss was
compensated by other proteins or isoforms of plectin.
Mutations in the exons common to all 8 isoforms (2-32) of this
one gene continue to be reported and classiﬁed within the main
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Figure 2.Double immunoﬂuorescencemicroscopyof human skin,muscle andheart tissue using antibodies to P1a (green) and an epitope shared betweenplectin isoforms
(red) and transmission electron microscopy of skin. In skin of patient V:1, P1a (A) is absent, whereas 10F6 staining at the BMZ is reduced (B and C). In control skin, P1a (D)
and the shared epitope of all plectin isoforms (10F6) (E) display a strong linear staining that co-localizes (F) at the BMZ. Note that the staining of dermal blood vessels
(arrowhead) with antibodies 10F6 is more dominant than that for P1a. Striated muscle of healthy controls shows no expression of P1a (G), whereas Z-disks clearly
stain for the shared epitope of plectin (H and I). Myocardium of healthy controls shows no expression of P1a (J), whereas Z-disks and intercalated disks stain strongly
for the shared plectin epitope (K and L). Bar in A corresponds to 25 μm for all immunoﬂuorescence images. Transmission electron microscopy of ultrathin sections
of patient skin (M and N). Lesional skin (M) reveals remnants of keratinocyte membranes (arrowheads) lining the blister ﬂoor ﬁtting with a ‘pseudo-junctional’ intra-
epidermal split level. The intact skin (N) shows hypoplastic hemidesmosomes (arrowheads). Bar in M corresponds to 2 μm for both EM images.
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phenotypic groups (Table 1). New PLECmutations resulting in EBS
are frequently reported and account for 8% of all cases of EBS (3).
However, except for one (13), all of them reside within exons that
are common to all isoforms (4). Epidermolysis bullosa simplex
with pyloric atresia (EBS-PA, [MIM 612138]) is characterized by
neonatal blistering, pyloric atresia and rapid clinical decline
(14). Epidermolysis bullosa simplex with muscular dystrophy
(EBS-MD,[MIM 226670]) displays congenital blistering and myop-
athy onset in later life (15). Additional myasthenic symptoms
have been reported in several patients having EBS-MD character-
izing yet another subtype, EBS-MD-Mys (16). An autosomal dom-
inant (AD) disease is EBS Ogna (EBS-O [MIM 131950]) with mild
Figure 3. DNA sequence analysis, immunoblotting and RT-PCR of P1a in patients. DNA sequencing of PLEC (A) revealed a homozygous mutation in exon 1a encoding the
isoform-speciﬁc sequence of P1a in patient V:1. A cytosine at position 46 is exchanged for a thymine (c.46C>T). This homozygous nucleotide change results in an arginine
at position 16 rendering a stop codon (p.Arg16X) in isoform 1a but not in any other plectin isoform (B). The isoform-speciﬁc exon 1a is highlighted in yellow. (C)
Immunoblotting of cell lysates from cultured keratinocytes derived from normal humans (lanes C) and patients (lanes V:1 and V:2). First panel (10F6): A marked
reduction (80–84%) of band intensity is seen for both patients using mAbs 10F6 which bind to the rod domain common to all isoforms of plectin, including P1a.
Because of the absence of P1a, the 10F6 signal (representing total plectin in skin) is reduced as expected. Arrow, position of plectin (molecular mass ∼ 500 kDa)
deduced from the position of molecular size markers (not shown). Second panel (P1a): P1a-speciﬁc antibodies show no detectable expression of the protein in
keratinocytes from patients, whereas P1a was markedly expressed in normal human keratinocytes. Arrow, as in ﬁrst panel. Third panel (DP2.15): Antibodies to human
desmoplakin I (250 kDa) and II (215 kDa) show normal expression of both proteins in both patients, similar to cultured keratinocytes from unaffected humans. Arrow,
position of desmoplakin I. (D) Quantitative RT-PCR of P1a (gray) and P1c (white) mRNA expression in cultured keratinocytes and ﬁbroblasts from human control (CK1-
3 and CF1,2, respectively) and corresponding patient (V:1,V:2) specimens. Bars represent expression relative to household gene B2M. Error bars, standard deviations of
experiments run in triplicates. Note the predominance of P1a above P1c in control keratinocytes (CK1-3), and the diminished expression in patient cells.
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skin fragility (17) that renders the plectin polypeptide vulnerable
to proteolysis (6). Of particular interest are the consequences of
mutations in the various ﬁrst exons because it is their tissue spe-
ciﬁcity which dictates disease manifestation. Comprehensive
understanding of isoform expression in different tissues is a
work in progress shared by different medical specialties. Recent-
ly, Gundesli et al. reported and characterized that mutations in
the ﬁrst coding exon of plectin isoform P1f are responsible for
limb-girdle muscular dystrophy (LGMD2Q) without any skin in-
volvement (13). Andrä et al. ﬁrst reported and characterized the
targeted cellular localization of P1a as the essential plectin
isoform present in the hemidesmosome co-localizing with the
integrin α6β4 subunit in mice (12). They suggested that this iso-
form was the culprit responsible for hereditary EBS in humans.
This was later conﬁrmed by Walko et al. who showed that hemi-
desmosome failure was caused by decreased levels of isoform
P1a in knock-in mice for dominantly inherited epidermolysis
bullosa simplex type Ogna (EBS-Ogna) (6). In mice, P1a is the pre-
dominant isoform that localizes to the epidermal BMZ (12). The
persistent expression of common plectin epitopes in the epider-
mal BMZ of our patients suggests that in humans, like in mice,
other plectin isoforms are co-expressed in the epidermal BMZ.
Compensation of the additional non-mutated isoforms known
to be expressed in the epidermis (i.e. P1c) did not preserve the
hemidesmosome architecture at adult age and led to skin fragil-
ity. However, both studied patients did not develop generalized
lesions until puberty implicating that perhaps compensation oc-
curred from their non-mutated isoforms during childhood.
The expression of P1a was absent in both normal human
striated and cardiac muscle tissues as shown in this study. Due
to the fact that the pathogenic mutation did not affect coding
exons shared by other isoforms whose role has previously
implicated Z-disks of striated muscle and intercalated disks of
myocardium, we do not expect development of myopathy or car-
diomyopathy. Moreover, late-onset plectin-mediated (cardio)
myopathy develops before the age of 30 years (18). The con-
sequence at the protein expression level of the homozygous
c. –27C > T variant of plectin isoform P1 is not known. In most
genes at this position TATA box promoter sequence elements
are surrounded byGC-rich sequences for transcription regulation
(19). In the case of c.–27C > T no such sequences can be distin-
guished. It is possible that c. –27C > Tmight be a rare polymorph-
ism, commonly present in the Turkish population.
In conclusion, we present and characterize the ﬁrst human
phenotype of the genodermatosis EBS caused by a homozygous
nonsense mutation in exon 1a of the PLEC gene. Our ﬁndings
uphold those of previous ones that have implicated P1a as




The patients (EB 315-01, V:1 and EB 315-02, V:2), were two sisters
diagnosed with EBS based on clinical ﬁndings, immunoﬂuores-
cence microscopy, electron microscopy and molecular analysis.
All experiments performed were done with material obtained
earlier for diagnostic purposes which did not require extra
approval from the institutional ethical committee. Patients
gave informed consent for the use of photographs and tissue
samples. All non-patient tissue samples were contributed and
analyzed anonymously. All experiments were conducted accord-
ing to the principles of the Declaration of Helsinki.
Immunoﬂuorescence antigen mapping
Four-mm skin biopsies of fresh blisters and healthy skin under
the left arm were taken for immunoﬂuorence antigen mapping
from both affected individuals. Immunoﬂuorescence antigen
mapping of skin biopsies and cultured human keratinocytes
were done as described before (21). The monoclonal antibodies
and their origin have been described previously (6,22,23). Mouse
monoclonal antibodies 10F6 were directed against an epitope in
plectin’s rod domain (24). Isoform-speciﬁc antibodies to P1a,
raised in rabbit against a synthetic peptide corresponding to a
12-amino acid residue-long sequence (KRTSSEDNLYLA) encoded
by human exon 1a, were used after afﬁnity-puriﬁcation (6,12,25);
the sequence of the peptide used as immunogen is conserved
between man, mouse and rat. Antibodies were diluted in PBS/
OVA 1% and sections were incubated at room temperature for 45
min. The secondary antibodies used for double staining were
green FITC-conjugated F(ab’)2 goat anti-rabbit IgG (1:50; Zymed
Laboratories, Carlsbad, CA) and red LRSC-conjugated donkey
anti-mouse IgG (1:50; Jackson Immuno Research, Newmarket,
UK). Validity of species-speciﬁc binding was ascertained by
cross experiments. Hoechst 33342 was used to stain nuclei.
Pictures of sectors were merged with Adobe Photoshop CS3
software.
Electron microscopy
Two-mm punch biopsies of perilesional and non-lesional skin
taken from the upper arm were obtained and prepared as
described previously (21).
Table 1. The plectinopathies
Subtype Exons affected Inheritance Organs affected Severity First reported case
EBS-MD 9–32 AR Skin, striated muscle, myocardium Severe and progressive Smith et al. (15)
EBS-MD-Mys 13,31,32 AR Skin, striated muscle Severe and progressive Selcen et al. (16)
EBS-PA Distal exons AR Skin, pylorus Lethala Charlesworth et al. (29)
EBS-Ogna 31 AD Skin Mild Koss-Harnes et al. (17)
EBS-plectin 1a 1a AR Skin Moderate This article
LGMD2Q 1f AR Striated muscle Severe and progressive Gundesli et al. (13)
Subtypes listed: epidermolysis bullosa simplex-muscular dystrophy (EBS-MD), epidermolysis bullosa simplex-muscular dystrophy withmyasthenic syndrome (EBS-MD-
Mys), epidermolysis bullosa simplex with pyloric atresia (EBS-PA), epidermolysis bullosa simplex type Ogna (EBS-Ogna), epidermolysis bullosa simplex with pathogenic
mutation in the ﬁrst coding exon (exon 1a) of isoform 1a (EBS-plectin 1a), limb-girdle muscular dystrophy (LGMD2Q). Inheritance: Autosomal recessive (AR), Autosomal
dominant (AD).
aOne nonlethal case has been reported (5).
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Molecular analysis
Genomic DNA was extracted from peripheral blood lympho-
cytes using standard laboratory methods. The PLEC gene en-
compassing the isoforms 1, 1a, 1b, 1c, 1d, 1e, 1f and 1g were
screened for mutations by sequencing analysis of all exons in-
cluding exon–intron boundaries. Primer sequences are available
upon request.
Western blotting
SDS–PAGE and western blotting were performed as described
previously (26,27). As substrate we used extracts from cultured
keratinocytes from our patients and healthy controls. After
SDS–PAGE and transfer onto nitrocellulose, the proteins were
identiﬁed with the same antibodies as used for immunoﬂuores-
cencemicroscopy; in addition antibodies DP 2.15 directed against
desmoplakin I/II (Abcam®) were used. To calculate plectin ex-
pression total protein content of patient and control extracts
were compared by running serial dilutions of all extracts on
SDS–PAGE gels. After visualization of the proteins with ‘Blue Sil-
ver’ staining (28) the gels were scanned and the intensity of stain-
ing of the lanes was used to calculate the relative protein content
of the different extracts. Next, serial dilutions were run on one
SDS–PAGE gel, and after western blotting plectin was visualized
with antibody 10F6. The blot was scanned and the relative plectin
expression was calculated from the intensity of staining using
Quantiscan software.
Quantitative RT-PCR (qRT-PCR)
For human samples, transcriptor universal cDNAmaster (Roche,
Basel, Switzerland) was used for reverse transcription of a single
RNA isolation of each cell population. P1a, P1c and the house-
keeping gene beta-2-microglobulin (B2M) were veriﬁed by qPCR
using FastStart Universal SYBR Master (Rox) reagent and an
Applied Biosystems 7900ht (Foster City, CA, USA). Primers used
are in Supplementary Material, Table S2.
Quantitative RT-PCR of mouse samples was performed as
previously described (Fig. S8 in ref 6). Estimated absolute copy
numbers of plectin isoforms were calculated from standard
curves obtained by serial dilutions of plasmids harboring the dif-
ferent exons. Values were normalized to hypoxanthine-guanine
phosphoribosyltransferase (HPRT) transcript levels.
Supplementary Material
Supplementary Material is available at HMG online.
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